Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB)of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the...
Read more








